CN116761599B - 氘代或部分氘代的n,n-二甲基色胺化合物 - Google Patents
氘代或部分氘代的n,n-二甲基色胺化合物 Download PDFInfo
- Publication number
- CN116761599B CN116761599B CN202180090269.1A CN202180090269A CN116761599B CN 116761599 B CN116761599 B CN 116761599B CN 202180090269 A CN202180090269 A CN 202180090269A CN 116761599 B CN116761599 B CN 116761599B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- compounds
- pharmaceutically acceptable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,938 | 2020-12-01 | ||
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2018955.1 | 2020-12-01 | ||
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3 | 2021-03-22 | ||
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 | 2021-03-22 | ||
| EPPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 | 2021-05-13 | ||
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556 | 2021-05-13 | ||
| EPPCT/EP2021/062794 | 2021-05-13 | ||
| GB2106881.2 | 2021-05-13 | ||
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116761599A CN116761599A (zh) | 2023-09-15 |
| CN116761599B true CN116761599B (zh) | 2025-05-30 |
Family
ID=99798988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180090269.1A Active CN116761599B (zh) | 2020-12-01 | 2021-11-18 | 氘代或部分氘代的n,n-二甲基色胺化合物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4031529B1 (enExample) |
| JP (1) | JP7834754B2 (enExample) |
| CN (1) | CN116761599B (enExample) |
| AU (1) | AU2021391581B2 (enExample) |
| CA (1) | CA3203020A1 (enExample) |
| IL (1) | IL303288A (enExample) |
| TW (1) | TWI891942B (enExample) |
| WO (1) | WO2022117359A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス， インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4433049A1 (en) * | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| AU2023361184A1 (en) | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| AU2024212866A1 (en) | 2023-01-23 | 2025-08-07 | Cybin Uk Ltd | Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent |
| US20240325351A1 (en) | 2023-03-31 | 2024-10-03 | Cybin UK Ltd. | Method of administration |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| TW202617141A (zh) | 2024-07-10 | 2026-05-01 | 英商賽本英國有限公司 | 包含氘化n,n-二甲基色胺之醫藥組合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337507A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| CN116056763B (zh) * | 2020-06-02 | 2024-03-05 | 赛本英国有限公司 | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581B2/en active Active
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
Non-Patent Citations (2)
| Title |
|---|
| Deuterated drugs: where are we now?;Graham S Timmins;《Expert Opin. Ther. Patents》;第24卷(第10期);第1-9页 * |
| INDOLEALKYLAMINE METABOLISM. SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES;Philip E. 等;《Journal of Labelled Compounds and Radiopharmaceuticals》(第6期);第455-465页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4031529A1 (en) | 2022-07-27 |
| TW202237565A (zh) | 2022-10-01 |
| EP4031529C0 (en) | 2023-09-27 |
| EP4275753A3 (en) | 2023-12-27 |
| EP4275753C0 (en) | 2026-03-18 |
| TWI891942B (zh) | 2025-08-01 |
| EP4275753B1 (en) | 2026-03-18 |
| CA3203020A1 (en) | 2022-06-09 |
| EP4275753A2 (en) | 2023-11-15 |
| JP2023551058A (ja) | 2023-12-06 |
| AU2021391581B2 (en) | 2026-06-18 |
| JP7834754B2 (ja) | 2026-03-24 |
| EP4031529B1 (en) | 2023-09-27 |
| WO2022117359A1 (en) | 2022-06-09 |
| AU2021391581A1 (en) | 2023-07-06 |
| IL303288A (en) | 2023-07-01 |
| CN116761599A (zh) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7834754B2 (ja) | 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物 | |
| US12251371B2 (en) | Deuterated or partially deuterated N,N-dimethyltryptamine compounds | |
| EP3844147B1 (en) | Compounds | |
| US11773062B2 (en) | Deuterated compounds | |
| EP4255421A1 (en) | Inhalable formulations | |
| US20220169606A1 (en) | Compositions and compounds for bioanalysis | |
| HK40103232A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818A (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| HK40078818B (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| CN116056763A (zh) | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 | |
| GB2605144A (en) | Deuterated compounds | |
| HK40056359A (en) | Compounds | |
| HK40056359B (en) | Compounds | |
| HK40060666A (en) | Method of synthesis | |
| HK40060666B (en) | Method of synthesis | |
| CN118450893A (zh) | 可注射和可吸入的制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: United Kingdom Address after: London Applicant after: Saiben UK Ltd. Address before: London Applicant before: SMAR Pharmaceutical Co.,Ltd. Country or region before: United Kingdom |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |